Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1204844 | 0.95 | MEN1 (0.31) | MEN1GAAKMT2A | |
| SCHEMBL11403455 | 0.81 | MAPT (0.34) | — | |
| SCHEMBL11395026 | 0.79 | MAPT (0.38) | — | |
| SCHEMBL3498626 | 0.78 | MAPK1 (0.38) | — | |
| SCHEMBL3498625 | 0.78 | MAPK1 (0.38) | — | |
| SCHEMBL11396426 | 0.77 | MAPT (0.33) | — | |
| SCHEMBL27617680 | 0.76 | SLC1A2 (0.31) | — | |
| SCHEMBL10657239 | 0.76 | MEN1 (0.49) | MEN1GAAKMT2A | |
| SCHEMBL5575605 | 0.75 | MAPT (0.53) | — | |
| SCHEMBL11856369 | 0.75 | MAPT (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200439-B1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160008336-A1 | HDAC INHIBITORS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| CN-101854804-B | Hdac inhibitors | LIXTE BIOTECHNOLOGY HOLDINGS INC | 2014-07-23 | — | — | CN | disclosed |
| US-8455688-B2 | HDAC inhibitors | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120178783-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY, INC. | 2012-07-12 | — | — | US | disclosed |
| US-8143445-B2 | HDAC inhibitors | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| CN-101854804-A | HDAC inhibitor | LIXTE BIOTECHNOLOGY HOLDINGS INC | 2010-10-06 | — | — | CN | disclosed |
| EP-2200439-A1 | HDAC INHIBITORS | Lixte Biotechnology, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090143445-A1 | HDAC Inhibitors | JOHN P. WHITE, ESQ | 2009-06-04 | — | — | US | disclosed |
| WO-2009045440-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY HOLDINGS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008336-A1 | HDAC INHIBITORS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY | HDAC5, HDAC1, HDAC4 | MEN1 4660/4885GAA 718/4885KMT2A 30/4885 |
| US-20120178783-A1 | HDAC INHIBITORS | HDAC3, HDAC4, HDAC7 | MEN1 2353/4885GAA 4142/4885KMT2A 186/4885 |
| US-20090143445-A1 | HDAC Inhibitors | HDAC3, HDAC7, HDAC4 | MEN1 2360/4885GAA 4109/4885KMT2A 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.